Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer
Provider
Journal of Patient-Reported Outcomes
Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID)
Lung Cancer
Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond
Investigational New Drugs
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
Current Treatment Options in Oncology
Novel Estrogen Receptor-Targeted Agents for Breast Cancer
Clinical Cancer Research
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Journal of Clinical Oncology
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
Gynecologic Oncology
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma
Cancer Treatment Reviews
The evolving landscape of antibody-drug conjugates in gynecologic cancers
Journal of Clinical Oncology
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study